Skip links

SciNeuro Participated in Alzheimer’s and Parkinson’s Disease Conference 2024, and Presented a Poster on Its Leading ASO Program SNP614

Rockville, Maryland, USA. March 12, 2024 – SciNeuro Pharmaceuticals, a clinical stage biotech company focused on developing treatments for neurodegenerative diseases, particularly Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), today announced its participation in the leading Alzheimer’s and Parkinson’s disease conference in Lisbon, March 5-9, 2024, and presented a poster for the leading ASO program – SNP614, targeting LRRK2 for Parkinson’s disease. The poster is titled “IN VIVO EFFICACY AND TOLERABILITY OF SNP614, A LRRK2 ANTISENSE OLIGONUCLEOTIDE AS POTENTIAL THERAPEUTIC AGENT FOR PARKINSON’S DISEASE”. An abstract is available on the conference website.

About SciNeuro Pharmaceuticals
SciNeuro Pharmaceuticals is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases. Since its founding in 2020, SciNeuro has built a portfolio of pipeline programs staged from discovery to clinical development by addressing three key disease-driving mechanisms of neurodegeneration – neurovascular inflammation, proteinopathy, and immune response. The company aims to develop disease-modifying treatment options for Alzheimer’s disease, Parkinson’s disease, and other devastating CNS diseases. To learn more, visit

SciNeuro Media Contact
Jessie Yang